axi-cel 与 liso-cel 治疗复发/难治性大 B 细胞淋巴瘤的匹配调整间接比较

In the absence of a randomized head-to-head trial, an unanchored matching-adjusted indirect comparison was performed to estimate the relative treatment effects of axicabtagene ciloleucel (axi-cel; ZUMA-1) versus lisocabtagene maraleucel (liso-cel; TRANSCEND-NHL-001) for treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least two lines of therapy. After matching, axi-cel and liso-cel had comparable objective response rates and duration. Compared to liso-cel, axi-cel was associated with improvements in overall survival (hazard ratio [HR]: 0.

53 [95% CI: 0. 34-0. 82]) and progression-free survival (HR: 0. 61 [95% CI: 0. 40-0. 92]). Axi-cel was associated with a higher rate of grade 3 cytokine release syndrome (odds ratio [OR]: 3. 64 [95% CI: 1. 04-12. 76]) and neurological events (OR: 3. 45 [95% CI: 1. 65-7. 19]), with smaller differences estimated in scenario analyses including ZUMA-1 safety management cohorts. Results suggest axi-cel improved survival compared to liso-cel but with increased odds of specific adverse events.